Use of glycoprotein IIb/IIIa inhibitors in unstable angina and non-ST-elevation myocardial infarction.
Acute coronary syndromes (ACS) are a major cause of morbidity and mortality in Western society. The commonest underlying pathology is the coronary atherosclerotic plaque complicated by thrombosis. Platelets play a central role. As the glycoprotein IIb/IIIa receptor is involved in the final step of platelet thrombus formation development and investigation of its blockage in ACS is at the fore. Initial hospital management of ACS occur in the ED setting. The present article outlines the above topics and clarifies the place of glycoprotein IIb/IIIa receptor inhibition in ED.
Crosbie
Deanne J
DJ
Pindara Emergency Centre, Pindara Private Hospital, Benowa, Queensland, Australia. crosmill@ozemail.com.au
D000077284:Abciximab; D000789:Angina, Unstable / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002543:Cerebral Hemorrhage / Q000139:chemically induced; D004635:Emergency Medicine / Q000379:methods / Q000592:standards; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D017410:Practice Guidelines as Topic; D018570:Risk Assessment / Q000379:methods; D013577:Syndrome; D013921:Thrombocytopenia / Q000139:chemically induced
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077284:Abciximab